Efficacy and safety of Cappra in erectile dysfunction patients

Completed

• Conditions: Mild and mild to moderate erectile dysfunction patients; Mental and Behavioural Disorders; Failure of genital response

• Registration Number: ISRCTN53582859
• Lead Sponsor: CAPP Innovation Research and Development Center (CIRD) (Thailand)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-05-28
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 70

Inclusion Criteria

1. Men aged 35 and above with mild and mild to moderate erectile dysfunction analyzed according to the International Index of Erectile Function-5 (IIEF-5)
2. All subjects must be sexually active and have sexual intercourse at least three times within 2 weeks

Exclusion Criteria

1. Patients with uncontrolled hypertension or uncontrolled diabetes mellitus within 3 months before enrollment into the study
2. Patients with liver or kidney dysfunction
3. Patients with active upper gastrointestinal bleeding
4. Patients who use any medications which may affect sexual function such as testosterone, phosphodiesterase type 5 inhibitor or any herbal substances claimed for improving sexual function
5. Patients who take medications which may have an interaction with Cappra, such as warfarin, antiplatelet agents, potassium sparing diuretics, monoamine oxidase inhibitors, and selective serotonin reuptake inhibitors
6. Patients who allergic to sulfonamide
7. Patients who allergic to honey or bee pollen
8. Patients with speech or reading problems
9. Participants also left the project when they could not comply with the study protocol, were unwilling to continue with the study or when the physician opined that patients may be harmed by the study protocol

Study & Design

• Study Type: Interventional
• Study Design: Not specified